Status:
RECRUITING
A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult
Lead Sponsor:
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions:
Health Adult Subjects
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group w...
Detailed Description
This is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamic profile of GR2303 Injection in healthy adult Chines...
Eligibility Criteria
Inclusion
- Healthy adult subjects
- Signed informed consent
Exclusion
- History or presence of any clinically significant organ system disease that could interfere with the objectives of the study or the safety of the subjects.
- Prior use of drug targeting TNF-like cytokine 1A
- history of malignant tumor
- psitive results for Hepatitis B surface antigen (HBsAg), anti Hepatitis C antibody (HCV Ab) or human immunodeficiency virus (HIV)
Key Trial Info
Start Date :
September 18 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 16 2026
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT07199270
Start Date
September 18 2025
End Date
December 16 2026
Last Update
September 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Friendship hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100050